OncLive

OncLive® serves as the official platform for the Oncology Specialty Group, which produces publications such as OncologyLive, Oncology Fellows, and Oncology Nursing News. The goal of OncLive® and its associated publications is to equip oncology professionals with essential resources and information to enhance patient care. Additionally, OncLive® features video programs like Peer Exchange, Insights, and News Network, offering engaging discussions filled with expert insights, opinions, and viewpoints on critical topics relevant to today's cancer care experts.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#290032

United States

#120428

Health/Health Conditions and Concerns

#279

Traffic sources

Monthly visitors

Articles

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

1 day ago | onclive.com | Courtney Flaherty

The ASCO Living Guidelines for stage IV non–small cell lung cancer (NSCLC) with driver alterations were updated in December 2024, making it more important than ever for oncologists to stay abreast of continually evolving treatment recommendations and effectively communicate these updates to patients, according to Fawzi F Abu Rous, MD.
Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS

2 days ago | onclive.com | Courtney Flaherty

Treatment with nadofaragene firadenovec-vncg (Adstiladrin) produced a high 3-month complete response (CR) rate of 75% in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1; n = 20), according to initial results from an ongoing phase 3 trial (NCT05704244) in Japan.1 In this study, the safety and efficacy of nadofaragene firadenovec are being evaluated in 2 cohorts comprising those with CIS...
Oncodetect Test Is Now Available for MRD Detection in Solid Tumors

2 days ago | onclive.com | Chris Ryan

NewsArticleApril 22, 2025 Oncodetect detects up to 200 ctDNA variants, providing a "detected" or "not detected" result and quantitative data for clinical decision-making. The test aids in adjuvant therapy decisions, treatment response evaluation, and monitoring for disease recurrence in solid tumor patients. Exact Sciences highlights the test's role in transforming cancer care by offering critical insights post-surgery and definitive therapy, enabling personalized care.
Early ESR1 Mutation Detection via ctDNA Monitoring Could Enhance Treatment Adaptation in HR+ Breast Cancer

2 days ago | onclive.com | Courtney Flaherty

CommentaryArticleApril 21, 2025Supplements and Featured PublicationsMolecular Testing and Evolving Treatment Strategies in HR+/HER2– Advanced Breast CancerVolume1 Issue 1Author(s):Fact checked by:Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.
China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors

3 days ago | onclive.com | Chris Ryan

China’s National Medical Products Administration has accepted a supplemental new drug application (sNDA) seeking the approval of repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions who have either progressed following prior therapies or have no satisfactory alternative treatment options.1 Repotrectinib was evaluated in patients with NTRK gene fusion–positive advanced solid tumors in the phase 1/2 TRIDENT-1...
Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung

3 days ago | onclive.com | Courtney Flaherty

Advances in treatment strategies for squamous cell carcinoma of the lung—including dual-targeting agents like ivonescimab (SMT112) and ongoing research on predictive biomarkers for immunotherapy response, and efforts to bolster the efficacy of first-line therapies—are offering new hope for improved treatment outcomes in this difficult-to-treat cancer subtype, according to Fawzi F Abu Rous, MD.
Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC

4 days ago | onclive.com | Courtney Flaherty

Expanding targeted therapy options in ALK- and EGFR-mutated non–small cell lung cancer (NSCLC) has complicated frontline decision-making, underscoring the importance of individualized treatment selection based on disease characteristics, toxicity profiles, and patient preferences, according to Isabel Preeshagul, DO, MBS. “These are all good options, and we are simply happy to have them.
The OncFive: Top Oncology Articles for the Week of 4/13

5 days ago | onclive.com | Kristi Rosa

Welcome to OncLive®’s OncFive!Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.
Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer

6 days ago | onclive.com | Courtney Flaherty

Given the association of CCNE1 amplification and cyclin E1 overexpression with poor treatment outcomes in high-grade serous ovarian cancer and the limited treatment arsenal for platinum-resistant disease, the potential use of cyclin E1 overexpression as a predictive biomarker of response to azenosertib is an important therapeutic avenue warranting further investigation, according to Fiona Simpkins, MD.
Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

6 days ago | onclive.com | Kyle Doherty

Ciltacabtagene autoleucel (cilta-cel; Carvykti) has solidified its status as a standard-of-care (SOC) treatment for patients with lenalidomide(Revlimid)-refractory multiple myeloma after 1 to 3 previous lines of therapy, according to María-Victoria Mateos, MD, PhD.